[go: up one dir, main page]

SV2017005577A - Metodos para diagnosticar y tratar el cancer - Google Patents

Metodos para diagnosticar y tratar el cancer

Info

Publication number
SV2017005577A
SV2017005577A SV2017005577A SV2017005577A SV2017005577A SV 2017005577 A SV2017005577 A SV 2017005577A SV 2017005577 A SV2017005577 A SV 2017005577A SV 2017005577 A SV2017005577 A SV 2017005577A SV 2017005577 A SV2017005577 A SV 2017005577A
Authority
SV
El Salvador
Prior art keywords
subject
methods
cancer
ntrk3
ntrk2
Prior art date
Application number
SV2017005577A
Other languages
English (en)
Inventor
Brian B Tuch
Josh Bilkener
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of SV2017005577A publication Critical patent/SV2017005577A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/575—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)

Abstract

SE IDENTIFICÓ UNA SERIE DE MUTACIONES PUNTUALES DIFERENTES EN NTRK1, NTRK2 Y NTRK3 EN MUESTRAS DE BIOPSIA DE SUJETOS QUE TENÍAN UNA SERIE DE DIFERENTES CÁNCERES. EN EL PRESENTE DOCUMENTO SE PROPORCIONAN MÉTODOS PARA TRATAR A UN SUJETO QUE TENGA CÁNCER, MÉTODOS PARA SELECCIONAR UN TRATAMIENTO QUE INCLUYA UN CANTIDAD TERAPÉUTICAMENTE EFICAZ DE UN INHIBIDOR DE TRK PARA UN SUJETO, MÉTODOS PARA DETERMINAR LA PROBABILIDAD DE QUE UN SUJETO QUE TIENE UN CÁNCER TENDRÁ UNA RESPUESTA POSITIVA AL TRATAMIENTO CON UN INHIBIDOR DE TRK, MÉTODOS PARA PREDECIR LA EFICACIA DE UN INHIBIDOR DE TRK EN UN SUJETO QUE TIENE UN CÁNCER, MÉTODOS PARA DETERMINAR EL RIESGO DE QUE UN SUJETO DESARROLLE UN CÁNCER Y MÉTODOS PARA AYUDAR EN EL DIAGNÓSTICO DEL CÁNCER QUE ESTÁN BASADOS EN LA IDENTIFICACIÓN DE UN SUJETO QUE TIENE UNA CÉLULA QUE TIENE AL MENOS UNA DE LAS MUTACIONES PUNTUALES EN NTRK1, NTRK2 Y/O NTRK3 O EN LA DETERMINACIÓN DE QUE EL SUJETO TIENE UNA CÉLULA QUE TIENE AL MENOS UNA DE LAS MUTACIONES PUNTUALES EN NTRK1, NTRK2 Y/O NTRK3. TAMBIÉN SE PROPORCIONAN KITS QUE PERMITEN LA DETECCIÓN DE AL MENOS UNA DE LAS MUTACIONES PUNTUALES EN NTRK1, NTRK2 Y/O NTRK3
SV2017005577A 2015-06-01 2017-12-01 Metodos para diagnosticar y tratar el cancer SV2017005577A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562169443P 2015-06-01 2015-06-01

Publications (1)

Publication Number Publication Date
SV2017005577A true SV2017005577A (es) 2018-04-17

Family

ID=56194562

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2017005577A SV2017005577A (es) 2015-06-01 2017-12-01 Metodos para diagnosticar y tratar el cancer

Country Status (19)

Country Link
US (2) US20180140604A1 (es)
EP (2) EP3303631A1 (es)
JP (1) JP2018526324A (es)
KR (1) KR20180021745A (es)
CN (1) CN107849615A (es)
AU (1) AU2016270803A1 (es)
BR (1) BR112017025773A2 (es)
CA (1) CA2988423A1 (es)
CL (1) CL2017003069A1 (es)
EA (1) EA201792679A1 (es)
HK (1) HK1253093A1 (es)
IL (1) IL256025A (es)
MA (2) MA44936A1 (es)
MX (1) MX2017015461A (es)
PE (1) PE20180329A1 (es)
PH (1) PH12017502200A1 (es)
SV (1) SV2017005577A (es)
TN (1) TN2017000502A1 (es)
WO (1) WO2016196671A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2952692C (en) 2008-09-22 2020-04-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds
PT3372605T (pt) 2008-10-22 2021-12-09 Array Biopharma Inc Compostos de pirazolo[1,5-a]pirimidina substituídos como inibidores de quinase trk
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
SMT201900203T1 (it) 2010-05-20 2019-05-10 Array Biopharma Inc Composti macrociclici come inibitori di trk chinasi
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
AU2013337277B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel NTRK1 fusion molecules and uses thereof
ES2949394T3 (es) 2012-11-05 2023-09-28 Found Medicine Inc Moléculas de fusión novedosas y usos de las mismas
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
CA2967951C (en) 2014-11-16 2023-11-07 Array Biopharma, Inc. Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
CA3003153A1 (en) 2015-10-26 2017-05-04 Loxo Oncology, Inc. Point mutations in trk inhibitor-resistant cancer and methods relating to the same
JP7061068B2 (ja) * 2015-12-18 2022-04-27 イグナイタ インコーポレイテッド 癌治療のための併用薬
PH12018502124B1 (en) 2016-04-04 2024-04-12 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
PT3458456T (pt) 2016-05-18 2020-12-07 Array Biopharma Inc Preparação de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidino-1-carboxamida
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
KR102718538B1 (ko) 2017-07-19 2024-10-21 이그니타, 인코포레이티드 엔트렉티닙을 포함하는 약학적 조성물
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
CN111225662B (zh) 2017-10-17 2022-11-22 伊尼塔公司 药物组合物和剂型
US20190247398A1 (en) * 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
CN109055562B (zh) * 2018-10-29 2022-12-20 深圳市颐康生物科技有限公司 一种生物标志物、预测肾细胞癌的复发和死亡风险的方法
WO2020243021A2 (en) * 2019-05-24 2020-12-03 Foundation Medicine, Inc. Ntrk fusion molecules and uses thereof
CN110643672A (zh) * 2019-10-15 2020-01-03 西安交通大学 高表达TrkB作为新型靶点在抑制胰腺癌转移方面的医药用途
KR20220008175A (ko) * 2020-07-13 2022-01-20 가톨릭대학교 산학협력단 전립선암 환자의 예후 진단 및 치료 전략 결정용 병리등급 특이적 마커
CN112779147A (zh) * 2020-12-23 2021-05-11 广西大学 一种流化状态对微生物聚集体微观传质及生化反应过程的测量方法及装置

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
AU7142201A (en) 2000-06-22 2002-01-02 Genentech Inc Agonist anti-trk-c monoclonal antibodies
WO2004082458A2 (en) * 2003-02-21 2004-09-30 The Johns Hopkins University Tyrosine kinome
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
DE102005003687A1 (de) 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
AU2006248780B2 (en) 2005-05-16 2010-06-03 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
MX2008002524A (es) 2005-08-25 2008-03-14 Creabilis Therapeutics Spa Conjugados polimericos de k-252a y sus derivados.
JP5160637B2 (ja) 2007-05-04 2013-03-13 アイアールエム・リミテッド・ライアビリティ・カンパニー ｃ−ｋｉｔおよびＰＤＧＦＲキナーゼインヒビターとしての化合物および組成物
HUE030929T2 (en) 2007-07-20 2017-06-28 Nerviano Medical Sciences Srl Substituted indazole derivatives active as kinase inhibitors
EA201000603A1 (ru) 2007-10-23 2010-12-30 Новартис Аг ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
KR101290503B1 (ko) 2008-01-17 2013-07-26 아이알엠 엘엘씨 개선된 항-ｔｒｋｂ 항체
ES2532732T3 (es) 2008-07-29 2015-03-31 Nerviano Medical Sciences S.R.L. Uso de un inhibidor de CDK para el tratamiento del glioma
CA2952692C (en) * 2008-09-22 2020-04-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds
PT3372605T (pt) * 2008-10-22 2021-12-09 Array Biopharma Inc Compostos de pirazolo[1,5-a]pirimidina substituídos como inibidores de quinase trk
CN102223885B (zh) 2008-11-24 2013-04-03 内尔维阿诺医学科学有限公司 用于治疗间皮瘤的cdk抑制剂
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
SMT201900203T1 (it) * 2010-05-20 2019-05-10 Array Biopharma Inc Composti macrociclici come inibitori di trk chinasi
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
SI2712358T1 (sl) 2011-05-13 2017-03-31 Array Biopharma, Inc. Spojine pirolidinil sečnine, pirolidinil tiosečnine in pirolidinil gvanidina kot inhibitorji kinaze trka
RU2014119150A (ru) 2011-11-14 2015-12-27 Тесаро, Инк. Модулирование некоторых тирозинкиназ
US9242977B2 (en) 2012-04-26 2016-01-26 Ono Pharmaceutical Co., Ltd. Trk-inhibiting compound
JP2013226108A (ja) * 2012-04-27 2013-11-07 Astellas Pharma Inc 新規ｎｔｒｋ２活性化変異の検出法
EP3290414B1 (en) 2012-05-23 2019-07-24 Nerviano Medical Sciences S.R.L. Crystalline form of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
JP2014082984A (ja) * 2012-10-23 2014-05-12 Astellas Pharma Inc 新規ｎｔｒｋ２活性化変異の検出法
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078378A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078417A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078408A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
ME02990B (me) 2012-11-13 2018-10-20 Array Biopharma Inc Jedinjenja n-pirolidinil, n'-pirazolil- uree, tiouree, guanidina i cijanoguanidina kао inhibitori trka kinaze
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9790210B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
EP3800183A1 (en) 2013-02-19 2021-04-07 ONO Pharmaceutical Co., Ltd. Urea derivatives as trk-inhibiting compounds
US10407509B2 (en) 2013-07-30 2019-09-10 Blueprint Medicines Corporation NTRK2 fusions
PL3097107T3 (pl) 2014-01-24 2020-01-31 Turning Point Therapeutics, Inc. Diarylowe związki makrocykliczne jako modulatory kinaz białkowych
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
MX2016014945A (es) 2014-05-15 2017-03-27 Array Biopharma Inc 1- ((3s,4r) -4- (3-fluorofenil) -1- (2-metoxietil) pirrolidin-3-il) -3- (4-metil-3- (2-metilpirimidin-5-il) -1-fenil-1h-pirazol-5-il) urea como inhibidor de trka cinasa.
MX2017002199A (es) 2014-08-18 2017-08-18 Ono Pharmaceutical Co Sal de adicion de acido de compuesto inhibidor de cinasa del receptor de trompomosina (trk).
CA2967951C (en) 2014-11-16 2023-11-07 Array Biopharma, Inc. Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate

Also Published As

Publication number Publication date
MA44936A1 (fr) 2021-09-30
US20180140604A1 (en) 2018-05-24
CL2017003069A1 (es) 2018-06-01
AU2016270803A1 (en) 2018-01-04
BR112017025773A2 (en) 2018-08-14
JP2018526324A (ja) 2018-09-13
TN2017000502A1 (en) 2019-04-12
US20220088021A1 (en) 2022-03-24
WO2016196671A1 (en) 2016-12-08
PH12017502200A1 (en) 2018-06-11
PE20180329A1 (es) 2018-02-13
KR20180021745A (ko) 2018-03-05
CN107849615A (zh) 2018-03-27
EA201792679A1 (ru) 2018-06-29
HK1253093A1 (zh) 2019-06-06
CA2988423A1 (en) 2016-12-08
EP3303631A1 (en) 2018-04-11
IL256025A (en) 2018-01-31
MX2017015461A (es) 2018-08-15
MA41667A1 (fr) 2018-08-31
EP3722441A1 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
SV2017005577A (es) Metodos para diagnosticar y tratar el cancer
SV2018005677A (es) Mutaciones puntuales en cancer resistente a trk y metodos relacionados con las mismas
MX2016010237A (es) Metodos de tratamiento de enfermedad de alzheimer.
CY1123067T1 (el) Μεθοδοι αγωγης ασθενων καρκινων με αναστολεις τρανσφερασης φαρνεσυλιου
BR112018075288A2 (pt) métodos para diagnóstico de infecções bacterianas e virais
EA201792642A1 (ru) Способы диагностики для т-клеточной терапии
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
MX2017010836A (es) Panel biomarcador para la deteccion de cancer.
MX2018008197A (es) Composiciones y metodos para cribar mutaciones en el cancer de tiroides.
BR112016006312A2 (pt) método e kit para determinar a presença ou ausência de staphylococcus aureus resistente à meticilina em uma amostra biológica
MX2022014633A (es) Metodos para detectar norovirus.
PE20160192A1 (es) Composiciones y metodo para tratar condiciones asociadas con el complemento
MX2021009528A (es) Prueba de diagnostico basada en fragmento de rgma.
MX2022010954A (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
MX374415B (es) Composiciones y métodos para identificar un riesgo de cáncer en un sujeto.
EA201990730A1 (ru) Рнк-биомаркеры для наследственного ангионевротического отека
MX2017006075A (es) Biomarcadores para la progresion de enfermedades en melanoma.
CY1122474T1 (el) Μεθοδος διαγνωσης νευραλγιας του τριδυμου
BR112016020043A2 (pt) composições e métodos para a identificação de malignidades de linfócitos b responsivas à terapia de depleção de linfócitos b
JOP20170191A1 (ar) طرق تشخيص و علاج السرطان
WO2019140008A3 (en) Methods for using dna methylation as a biomarker for identification and treatment of metabolic syndrome
CY1119986T1 (el) Παραγοντας ανοσο-απεικονισης για χρηση στην θεραπεια με συζευγμα αντισωματος-φαρμακου
PL410049A1 (pl) Sposób wykrywania zwiększonego ryzyka zachorowania na raka skóry oraz zastosowania genotypowego wariantu genu GRHL3
CY1119998T1 (el) Παραγοντας ανοσο-απεικονισης για χρηση στην θεραπεια με συζευγμα αντισωματος-φαρμακου
BR112016018408A2 (pt) moléculas de anticorpo à lag-3 e usos das mesmas